1. Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer. 1994;73:2296–2304.
2. Pulmonary complications of bone marrow transplantation. Chest. 1996;109:1066–1077.
3. Pulmonary complications in patients with haematological malignancies treated at a respiratory ICU. Eur Respir J. 1998;12:116–122.
4. Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann Hematol. 1999;78:73–77.
5. Role of alveolar macrophages in pulmonary neoplasias. Biochim Biophys Acta. 1986;823:227–245.
6. Bronchoalveolar lavage and the immunology of primary lung cancer. Chest. 1985;87:677–683.
7. Defective cytostatic activity of pulmonary alveolar macrophages in primary lung cancer. Chest. 1990;98:851–885.
8. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984;100:345–351.
9. Fever and infection in leukemic patients—a study of 494 consecutive patients. Cancer. 1978;41:1610–1622.
10. Causes of death in cancer patients. Cancer. 1974;33:568–573.
11. Potential sites of infection that develop in febrile granulocytopenic patients. Leuk Lymphoma. 1993;10:461–467.
12. Bacterial pneumonia in recipients of bone marrow transplantation. A five-year prospective study. Transplantation. 1995;60:672–678.
13. Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. Lung Cancer. 2008;62:381–384.
14. Outbreak of Stenotrophomonas maltophilia bacteremia in allogeneic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis. 2000;30:195–197.
15. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant. 2007;40:63–70.
16. The spectrum of pulmonary infections in cancer patients. Curr Opin Oncol. 2001;13:218–223.
17. Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT. AJR Am J Roentgenol. 1997;169:1347–1353.
18. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45:1602–1609.
19. Bacteremic pneumonia in neutropenic patients with cancer. Arch Intern Med. 1998;158:868–872.
20. Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteremia in cancer patients. J Infect. 2012;65:521–527.
21. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–1754.
22. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388–416.
23. Legionella pneumonia in cancer patients. Medicine (Baltimore). 2008;87:152–159.
24. Clinical features of Stenotrophomonas maltophilia pneumonia in immunocompromised patients. Respir Med. 1996;90:35–38.
25. Systemic nocardiosis following allogeneic bone marrow transplantation. Transpl Infect Dis. 2003;5:16–20.
26. Nocardiosis after bone marrow transplantation: a retrospective study. Clin Infect Dis. 1997;24:1154–1160.
27. Extrapulmonary tuberculosis active infection misdiagnosed as cancer: Mycobacterium tuberculosis disease in patients at a Comprehensive Cancer Center (2001–2005). Cancer. 2005;104:2882–2887.
28. Tuberculosis in acute leukemia: a clinico-hematological profile. Hematology. 2006;11:335–340.
29. Risk factors for pulmonary tuberculosis in bone marrow transplant recipients. Am J Respir Crit Care Med. 1998;158:1173–1177.
30. Tuberculosis in blood and marrow transplant recipients. Hematol Oncol. 2002;20:51–62.
31. Mycobacterial infections in adult patients with hematological malignancy. Eur J Clin Microbiol Infect Dis. 2012;31:1059–1066.
32. Nontuberculous mycobacteria. Am J Transplant 2004;4(Suppl. 10):42–46.
33. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.
34. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102:827–833.
35. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008;47:1176–1184.
36. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis. 1998;26:1092–1097.
37. Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore). 1970;49:147–173.
38. Invasive aspergillosis. N Engl J Med. 1976;295:655–658.
39. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med. 1987;317:1105–1108.
40. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia. Am Rev Respir Dis. 1985;131:115–120.
41. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821.
42. Diagnosis of invasive fungal infections in hematology and oncology–guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003;82:S141–S148.
43. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica. 2006;91:986–989.
44. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139–147.
45. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect. 2001;7:54–61.
46. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373–379.
47. Invasive pulmonary aspergillosis following bone marrow transplantation: risk factors and diagnostic aspect. Haematologia (Budap). 2002;32:427–437.
48. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med. 1996;100:171–178.
49. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. Am J Med. 1986;81:249–254.
50. Diagnosing fungal infections in immunocompromised hosts. J Clin Pathol. 1992;45:1–5.
51. Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients–guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003;82:S118–S126.
52. Overview: non-fumigatus species of Aspergillus: perspectives on emerging pathogens in immunocompromised hosts. Curr Opin Investig Drugs. 2001;2:1366–1367.
53. Aspergillus terreus: an emerging Amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer. 2004;101:1594–1600.
54. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004;190:641–649.
55. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42:1417–1727.
56. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann Oncol. 2008;19:984–989.
57. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol. 2004;42:5517–5522.
58. Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases—the role of factors affecting assay performance. Int J Infectious Diseases. 2011;15:e874–e881.
59. Polymerase chain reaction in the diagnosis of invasive aspergillosis. Mycoses. 2004;47:338–342.
60. Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol. 2012;89:120–127.
61. Diagnosis of invasive fungal disease using serum (1→3)- β -D-glucan: a bivariate meta-analysis. Intern Med. 2011;50:2783–2791.
62. Voriconazole versus Amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;34:408–415.
63. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis. 2005;40:1684–1688.
64. Isavuconazole versus Voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2015;387:760–769.
65. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis. 2006;43:1060–1068.
66. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–360.
67. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457–462.
68. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004;100:568–573.
69. Non-Aspergillus fungal pneumonia in transplant recipients. Clin Chest Med. 2005;26:675–690.
70. Imaging of pulmonary fusariosis in patients with hematologic malignancies. AJR Am J Roentgenol. 2008;190:1605–1609.
71. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40:89–99.
72. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24:307–312.
73. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:710–718.
74. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis. 1991;164:731–740.
75. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989. 1993 and 1997. Pathol Int. 2003;53:744–750.
76. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975;36:2004–2009.
77. Pneumocystis carinii pneumonia in patients with cancer. An increasing incidence. Cancer. 1993;71:481–485.
78. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med. 1995;155:2436–2441.
79. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years’ experience of infection in GIMEMA centres. Br J Haematol. 2002;117:379–386.
80. Comparison of histologic stains in the diagnosis of Pneumocystis carinii. Acta Cytol. 1995;39:1124–1127.
81. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988;318:589–593.
82. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007;132:1305–1310.
83. Coccidioidomycosis in hematopoietic stem cell transplant recipients. Med Mycol. 2005;43:705–710.
84. Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study. Clin Microbiol Infect. 2008;14:1160–1166.
85. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation. 1998;66:1330–1334.
86. Thin-section CT findings in 32 immunocompromised patients with cytomegalovirus pneumonia who do not have AIDS. AJR Am J Roentgenol. 2003;181:1059–1063.
87. Pulmonary cytomegalovirus infection in immunocompromised patients. Chest. 2001;119:838–843.
88. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Bone Marrow Transplant. 2001;28:485–490.
89. Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clin Infect Dis. 1993;17:S392–S399.
90. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006;85:278–287.
91. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med. 1997;102:10–18.